Drug intelligence / Profile preview

plumbagin

Development stage
Preclinical
Modality
Small Molecules
01

Overview

Plumbagin is a naturally occurring naphthoquinone compound (C11H8O3) originally isolated from plants of the genus Plumbago and also found in other plant genera such as Drosera, Nepenthes, and black walnut. It is an orange crystalline powder with diverse biological activities. Mechanistically, plumbagin exhibits anticancer properties by inactivating signaling pathways including Akt/NF-kB, MMP9, and VEGF. It induces apoptosis in cancer cells through the generation of reactive oxygen species (ROS), inhibits NADPH oxidase 4 activity, activates Nrf2-mediated antioxidant response elements leading to upregulation of cytoprotective genes like NQO1 and heme oxygenase‑1, and inhibits tumor angiogenesis via effects on VEGF receptor‑2 signaling. Additionally, it has demonstrated antibacterial, antifungal, tuberculostatic activities as well as antifeedant effects against worms[1][3][9]. Plumbagin is considered genotoxic and mutagenic[2].

Other names
5-hydroxy-2-methyl-1,4-naphthoquinone2-methyljugloneplumbagineplumaginplumbapinPLUMBAGANPlumbaeinplumbagoneOphioxylin
02

Targets

AKT (RAC-alpha serine/threonine-protein kinase)MMP9 (Matrix metalloproteinase-9)NOX4 (NADPH oxidase 4)NF-κBNFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on plumbagin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on plumbagin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call